Abbott's MitraClip Class I Recall Results From Delivery Snafus
This article was originally published in The Gray Sheet
Abbott plans to require additional training for physicians implanting the mitral valve repair device and to add a new warning to the device’s labeling after nine instances in which users could not properly deploy the system.
You may also be interested in...
CMS finalized a national coverage determination for transcatheter mitral valve repair, conditioned on a registry and on minimum facility and experience requirements for hospitals. The policy follows close behind a new-technology add-on payment granted to Abbott’s MitraClip device.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.
Gallium has been approved as a diagnostic agent by the US agency to help early detection of prostate cancer spread in patients who qualify for treatment with surgery or radiation therapy.